In a regulatory filing, BD said it 1st thought to use some $9.1 million in debt to finance the non-cash portion of the deal. But an analysis of its cash position revealed that the Franklin Lakes, N.J.-based medical device giant "can use a greater portion of its cash on hand in a tax efficient manner" for the buyout, according to the filing.
BD said that means it will take on debt of $7.7 billion for the acquisition, including a $1 billion, 364-day term loan.
"As a result of this lower amount of acquisition-related indebtedness, in combination with an expected interest rate in a range of approximately 2.75% to 3.25%, BD now expects that the acquisition will be accretive to cash earnings per share on a high-teen percentage basis in the 1st full year following consummation of the acquisition,” Becton said.
When it announced the deal in early October, BD said it didn’t expect the CareFusion merger to be accretive to net earnings until fiscal 2018.
Last week the companies said the merger passed the waiting period mandated by U.S. anti-trust laws.